Key facts
- US FDA will review an AI-based tool.
- The tool is designed to predict drug-related liver damage.
- This review signifies progress in AI adoption for drug safety monitoring.
The U.S. Food and Drug Administration (FDA) is set to review an artificial intelligence-based tool. This tool has been developed with the specific purpose of predicting potential liver damage caused by drugs. The decision by the FDA to undertake this review is seen as a notable advancement in the integration of AI technologies within the pharmaceutical industry, particularly for enhancing drug safety monitoring processes.